Chloroprocaine 50mg/5ml solution for injection ampoules
Requires a prescription from a doctor or prescriber
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Chloroprocaine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Chloroprocaine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Chloroprocaine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Chloroprocaine on the MHRA register
Ampres 50mg/5ml solution for injection ampoules
Therapeutically similar medicines
Injectables
(3)Topicals
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 25 · 2004–2026
Showing the 50 most relevant studies, sorted by most relevant.
Saporito A, Ceppi M, Perren A, et al.
2025
A. Saporito, M. Ceppi, A. Perren, et al.
Journal of clinical anesthesia, 2019
Sharawi N, Williams M, Athar W, et al.
2023
- Analgesia, Obstetrical
- Anesthesia, Epidural
- Labor, Obstetric
ImportanceDural-puncture epidural (DPE) and standard epidural are common modes of neuraxial labor analgesia. Little is known about conversion of DPE-initiated labor analgesia to surgical anesthesia for cesarean delivery.ObjectiveTo determine whether DPE provides a faster onset and better-quality block compared with the standard epidural technique for cesarean delivery.Design, setting, and participantsThis double-blind, randomized clinical trial was conducted between April 2019 and October 2022 at a tertiary care university hospital (University of Arkansas for Medical Sciences). Participants included women aged 18 years and older undergoing scheduled cesarean delivery with a singleton pregnancy.InterventionsParticipants were randomized to receive DPE or standard epidural in the labor and delivery room. A T10 sensory block was achieved and maintained using a low concentration of bupivacaine with fentanyl through the epidural catheter until the time of surgery. Epidural extension anesthesia was initiated in the operating room.Main outcomes and measuresThe primary outcome was the time taken from chloroprocaine administration to surgical anesthesia (T6 sensory block). The secondary outcome was the quality of epidural anesthesia, as defined by a composite of the following factors: (1) failure to achieve a T10 bilateral block preoperatively in the delivery room, (2) failure to achieve a surgical block at T6 within 15 minutes of chloroprocaine administration, (3) requirement for intraoperative analgesia, (4) repeat neuraxial procedure, and (5) conversion to general anesthesia.ResultsAmong 140 women (mean [SD] age, 30.1 [5.2] years), 70 were randomized to the DPE group, and 70 were randomized to the standard epidural group. The DPE group had a faster onset time to surgical anesthesia compared with the standard epidural group (median [IQR], 422 [290-546] seconds vs 655 [437-926] seconds; median [IQR] difference, 233 [104-369] seconds). The composite rates of lower quality anesthesia were 15.7% (11 of 70 women) in the DPE group and 36.3% (24 of 66 women) in the standard epidural group (odds ratio, 0.33; 95% CI, 0.14-0.74; P = .007).Conclusions and relevanceAnesthesia initiated following a DPE technique resulted in faster onset and improved block quality during epidural extension compared with initiation with a standard epidural technique. Further studies are needed to confirm these findings in the setting of intrapartum cesarean delivery.Trial registrationClinicalTrials.gov Identifier: NCT03915574.
Abstract licence: CC BY
An Teunkens, K. Vermeulen, E. Van Gerven, et al.
Regional Anesthesia & Pain Medicine, 2016
Lee LO, Ramirez-Chapman AL, White DL, et al.
2023
- Morphine
- Analgesia, Epidural
- Pruritus
Tianzhen Ji, Can Jiang, Hongxia Liu, et al.
Pain and Therapy, 2024
Jing Yu, Jingjing Liu, Chenran Wang, et al.
Frontiers in Pharmacology, 2024
Michele Figus, Fabrizio Giansanti, E. Villani, et al.
Journal of Ocular Pharmacology and Therapeutics, 2024
- Cataract
- Cataract Extraction
- Phacoemulsification
Zhang P, Zhang J, Zhao Y, et al.
2025
Priti Sherikar, Minna Osheen, M. Mitragotri, et al.
Indian Journal of Pain, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
3.1 minutes
Mechanism
Chloroprocaine acts mainly by binding to the alpha subunit on the cytoplasmic re…
Food interactions
None known
Human targets
3 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
6 to 12 minutes
[L43377][L43382][L43402]
…
Half-life
21 seconds
Protein binding
[L43402]
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L43377]
It is also indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, and a preservative-free form can also be used for lumbar and caudal epidural blocks.
[L43382]
Topical chloroprocaine for ophthalmic use is indicated for ocular surface anesthesia.
[L43387]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1780 interactions
If there are any changes, oxygen should be administered.
[L43377][L43382]
In patients with chloroprocaine overdose with convulsions, underventilation or apnea, the drug label recommends giving immediate attention to maintaining a patent airway, assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. If convulsions persist, provide small increments of an ultra-short acting barbiturate or a benzodiazepine intravenously. Refer to the chloroprocaine drug label for a complete description of the procedures recommended in case of overdose.
[L43377][L43382]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L43377][L43382][L43402]
The duration of chloroprocaine-induced anesthesia may be up to 60 minutes. The absorption rate of local anesthetics depends on the total dose and concentration of chloroprocaine, as well as the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic injection. The presence of epinephrine reduces the rate of absorption and plasma concentration of local anesthetics.
[L43377][L43382]
The systemic exposure to chloroprocaine following its topical ocular administration has not been evaluated.
[L43387]
[L43382]
Following intrapartum epidural anesthesia, the apparent in vivo half-life of chloroprocaine detected in maternal plasma was 3.1 minutes (range from 1.5 to 6.4 minutes).
[L43377]
[L43402]
[L43387]
The hydrolysis of chloroprocaine leads to the production of ß-diethylaminoethanol and 2-chloro-4-aminobenzoic acid, which inhibits the action of the sulfonamides.
[L43377][L43382][L43387]
[L43377][L43382][L43387]
Proteins and enzymes this drug interacts with in the body
The influx of Na(+) ions provokes membrane depolarization, initiating the propagation of electrical signals throughout cells and tissues .
PMID:15385606 PMID:16988069 PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784 PMID:25240195 PMID:26680203 PMID:7720699
Nav1.7 plays a crucial role in controlling the excitability and action potential propagation from nociceptor neurons, thereby contributing to the sensory perception of pain PMID:17145499 PMID:17167479 PMID:19369487 PMID:24311784
PMID:29499166 PMID:30388404
Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary water intake to regulate sodium homeostasis (By similarity)
PMID:10375632 PMID:11093780 PMID:1406597 PMID:15505207 PMID:19478460 PMID:39112701 PMID:39112703 PMID:39112705 PMID:8302271
Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC S01HA08
ATC N01BA04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Chloroprocaine
Additional database identifiers
Drugs Product Database (DPD)
5999
ChemSpider
8293
BindingDB
50239963
ZINC
ZINC000001530938
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10585
GenAtlas
SCN1A
GeneCards
SCN1A
GenBank Gene Database
AF225985
GenBank Protein Database
12642270
Guide to Pharmacology
578
UniProt Accession
SCN1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10582
GenAtlas
SCN10A
GeneCards
SCN10A
GenBank Gene Database
AF117907
GenBank Protein Database
4838145
Guide to Pharmacology
585
UniProt Accession
SCNAA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10583
GenAtlas
SCN11A
GeneCards
SCN11A
GenBank Gene Database
AF188679
GenBank Protein Database
6572950
UniProt Accession
SCNBA_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10588
GenAtlas
SCN2A
GeneCards
SCN2A
GenBank Gene Database
M94055
GenBank Protein Database
457879
Guide to Pharmacology
579
UniProt Accession
SCN2A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10590
GenAtlas
SCN3A
GeneCards
SCN3A
GenBank Gene Database
AJ251507
GenBank Protein Database
7414320
Guide to Pharmacology
580
UniProt Accession
SCN3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10591
GenAtlas
SCN4A
GeneCards
SCN4A
GenBank Gene Database
M81758
GenBank Protein Database
338213
Guide to Pharmacology
581
UniProt Accession
SCN4A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10593
GenAtlas
SCN5A
GeneCards
SCN5A
GenBank Gene Database
M77235
GenBank Protein Database
184039
Guide to Pharmacology
582
UniProt Accession
SCN5A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10594
GeneCards
SCN7A
UniProt Accession
SCN7A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10596
GenAtlas
SCN8A
GeneCards
SCN8A
GenBank Gene Database
AF050736
GenBank Protein Database
4321647
Guide to Pharmacology
583
UniProt Accession
SCN8A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10597
GenAtlas
SCN9A
GeneCards
SCN9A
GenBank Gene Database
X82835
GenBank Protein Database
758110
Guide to Pharmacology
584
UniProt Accession
SCN9A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:799
GenAtlas
ATP1A1
GeneCards
ATP1A1
GenBank Gene Database
D00099
GenBank Protein Database
219942
UniProt Accession
AT1A1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11049
GenAtlas
SLC6A3
GeneCards
SLC6A3
GenBank Gene Database
M96670
GenBank Protein Database
553260
Guide to Pharmacology
927
UniProt Accession
SC6A3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72